Sermorelin
Sermorelin is a peptide, indexed here under GHRH analogues.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | GHRH analogues |
| CAS registry number | 86168-78-7[1] |
| PubChem CID | 16132413[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C149H246N44O42S[1] |
| Molecular weight | 3357.9 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Sermorelin corresponds to the 1-29 fragment of growth hormone releasing hormone. A 1999 BioDrugs review covers its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency, and a 2006 Clinical Interventions in Aging paper discusses adult-onset growth hormone insufficiency.
Receptor-level work in the retrieved set is older: a 1985 Endocrinology paper examines the interaction of growth hormone-releasing factor and 14 analogues with the vasoactive intestinal peptide receptor, and a second 1985 Endocrinology paper examines structural requirements for activation of rat anterior pituitary adenylate cyclase. A 2021 Annals of Translational Medicine paper reports on recurrent glioma.
[3, 4, 5, 6, 7]Reported mechanism
A growth hormone releasing factor analogue acting at the GHRH receptor on the anterior pituitary, upstream of growth hormone release.
[6]Stated in the title of the cited 1985 Endocrinology paper on activation of rat anterior pituitary adenylate cyclase by growth hormone releasing factor.
Targets named in the cited records: GHRH receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Sermorelin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- GRF 1-29
- GHRH 1-29
- geref
Where this page sits
Research records
Cited research records for Sermorelin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Sermorelin
Compounds indexed next to it
- Tesamorelin — GHRH analogues
- CJC-1295 — GHRH analogues
- Somatostatin — Endocrine and immune signalling peptides
- Somatropin — Growth factors and growth hormone-derived compounds
Named targets in the cited records
Class page: GHRH analogues. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Sermorelin?
Sermorelin corresponds to the 1-29 fragment of growth hormone releasing hormone. A 1999 BioDrugs review covers its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency, and a 2006 Clinical Interventions in Aging paper discusses adult-onset growth hormone insufficiency.
Which class is Sermorelin indexed under?
Sermorelin is indexed under GHRH analogues. GHRH analogues are peptides modelled on growth hormone releasing hormone, which act at the GHRH receptor on the anterior pituitary.
What does the FDA application register show for Sermorelin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 16132413, Sermorelin. PubChem, National Library of Medicine (2026). pubchem:16132413
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:sermorelin
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs (1999). pmid:18031173
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging (2006). pmid:18046908
- Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology (1985). pmid:2859987
- Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes. Endocrinology (1985). pmid:2994998
- A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med (2021). pmid:33842627
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.